This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Aug 1;36(22):2323-2325.

doi: 10.1200/JCO.2018.78.7390. Epub 2018 Jun 12.

Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies

Josh Sopp¹, Mark S Cragg¹

Affiliations

PMID: 29894272
DOI: 10.1200/JCO.2018.78.7390

Comment

Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies

Josh Sopp et al. J Clin Oncol. 2018.

. 2018 Aug 1;36(22):2323-2325.

doi: 10.1200/JCO.2018.78.7390. Epub 2018 Jun 12.

Authors

Josh Sopp¹, Mark S Cragg¹

Affiliation

¹ Josh Sopp and Mark S. Cragg, University of Southampton, Southampton, United Kingdom.

PMID: 29894272
DOI: 10.1200/JCO.2018.78.7390

No abstract available

PubMed Disclaimer

Comment on

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

24721/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations